Journal Article
. 2010 Sep; 16(9):678-86.

Colony-stimulating factor prescribing patterns in patients receiving chemotherapy for cancer

Scott D Ramsey 1 Jeannine S McCune  David K Blough  Cara L McDermott  Lauren Clarke  Jennifer L Malin  Sean D Sullivan  
  • PMID: 20873955
  •     18 citations


Objective: To examine variables influencing colony-stimulating factor (CSF) prescription as primary prophylaxis versus other use during patients' initial chemotherapy course among a large sample of health insurance records.

Study Design: Retrospective cohort study.

Methods: Adults 25 years or older with a diagnosis of breast, colorectal, or non-small cell lung cancer (NSCLC) between January 1, 2002, and December 31, 2005, were identified from the western Washington State Surveillance, Epidemiology, and End Results Seattle Puget Sound registry. We linked these records to health insurance claims. Chemotherapy regimens identified from insurance claims were categorized as carrying high, intermediate, or low risk of myelosuppression according to the National Comprehensive Cancer Network guidelines and the literature. Colony-stimulating factor use was described as primary prophylaxis, other use, or no use, and logistic regression analysis identified factors associated with CSF use.

Results: For patients with breast cancer, colorectal cancer, and NSCLC, respectively, 58%, 0%, and 28% received CSFs as primary prophylaxis in conjunction with high-risk chemotherapy regimens, whereas 10%, 7%, and 21% did so in conjunction with low-risk chemotherapy regimens. Prophylactic CSF use increased from 2002 to 2005 for breast cancer but remained constant for colorectal cancer and for NSCLC.

Conclusions: As primary prophylaxis, CSF use is underutilized based on recommendations for patients having cancer who receive chemotherapy regimens carrying high febrile neutropenia risk and may be overutilized for patients who receive chemotherapy regimens carrying low febrile neutropenia risk. Further research is needed to understand the barriers to implementing guidelines in clinical practice.

Other Links

Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.
Arnold L Potosky, Jennifer L Malin, +4 authors, Jane C Weeks.
J Natl Cancer Inst, 2011 Jun 15; 103(12). PMID: 21670423    Free PMC article.
Physician characteristics and variability of erythropoiesis-stimulating agent use among Medicare patients with cancer.
Jason D Wright, Alfred I Neugut, +4 authors, Dawn L Hershman.
J Clin Oncol, 2011 Aug 04; 29(25). PMID: 21810679    Free PMC article.
A way forward on the medically appropriate use of white cell growth factors.
Thomas J Smith, Bruce E Hillner.
J Clin Oncol, 2012 Mar 01; 30(14). PMID: 22370327    Free PMC article.
Colony-stimulating factors for febrile neutropenia during cancer therapy.
Charles L Bennett, Benjamin Djulbegovic, LeAnn B Norris, James O Armitage.
N Engl J Med, 2013 Mar 22; 368(12). PMID: 23514290    Free PMC article.
Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.
Geralyn E Waters, Patricia Corrigan, Mandy Gatesman, Thomas J Smith.
J Oncol Pract, 2013 Aug 15; 9(4). PMID: 23942922    Free PMC article.
Use of colony-stimulating factor in patients with ovarian cancer receiving paclitaxel and carboplatin in Japan.
Kenichi Harano, Akihiro Hirakawa, +3 authors, Noriyuki Katsumata.
J Gynecol Oncol, 2014 Apr 25; 25(2). PMID: 24761216    Free PMC article.
Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992-2009.
Yefei Zhang, Shuang-Shuang Fu, Xianglin L Du.
Med Oncol, 2014 Sep 19; 31(10). PMID: 25231751
G-CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use.
Gisoo Barnes, Ashutosh Pathak, Lee Schwartzberg.
Cancer Med, 2014 Nov 21; 3(6). PMID: 25410813    Free PMC article.
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer.
Fotios Loupakis, Alexander Stein, +3 authors, Pia Österlund.
Target Oncol, 2015 Dec 22; 11(3). PMID: 26687849    Free PMC article.
Safety and tolerability of Peg-grafeelâ„¢, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India.
Vineet Talwar, Sharanabasappa S Nirni, +2 authors, Nitu Sinha.
South Asian J Cancer, 2017 Apr 18; 6(1). PMID: 28413791    Free PMC article.
A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.
Aasthaa Bansal, Sean D Sullivan, +4 authors, Scott D Ramsey.
J Comp Eff Res, 2017 Jul 08; 6(5). PMID: 28686055    Free PMC article.
Medication overuse in oncology: current trends and future implications for patients and society.
Stephen M Schleicher, Peter B Bach, Konstantina Matsoukas, Deborah Korenstein.
Lancet Oncol, 2018 Apr 04; 19(4). PMID: 29611528    Free PMC article.
Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level.
Hassam Baig, Barbara Somlo, +3 authors, Phuong K Morrow.
J Oncol Pharm Pract, 2018 Sep 12; 25(7). PMID: 30200842    Free PMC article.
A Survey of Oncologists' Perceptions and Opinions Regarding the Use of Granulocyte Colony-Stimulating Factors.
Alicia Hawkins, Alysa Murphy, +3 authors, Michael A Kelsh.
J Cancer Educ, 2019 Oct 28; 35(1). PMID: 31656028    Free PMC article.
Algorithm to Identify Systemic Cancer Therapy Treatment Using Structured Electronic Data.
Nikki M Carroll, Kate M Burniece, +3 authors, Debra P Ritzwoller.
JCO Clin Cancer Inform, 2017 Nov 01; 1. PMID: 30657379    Free PMC article.
Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
Shuling Li, Jiannong Liu, +4 authors, David Chandler.
Support Care Cancer, 2019 Oct 19; 28(6). PMID: 31624920
Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy.
Prasad L Gawade, Shuling Li, +4 authors, Brian D Bradbury.
Support Care Cancer, 2020 Jan 11; 28(9). PMID: 31919669    Free PMC article.
Predicting neutropenia risk in patients with cancer using electronic data.
Pamala A Pawloski, Avis J Thomas, +3 authors, Gary H Lyman.
J Am Med Inform Assoc, 2016 Sep 18; 24(e1). PMID: 27638907    Free PMC article.